Ceremedy is a Copenhagen-based biotech company focused on drug discovery for
the treatment of CNS disorders. The company was founded in 2018 as a spin-off
from the University of Copenhagen.
We perform intelligent medicinal chemistry and structure-based drug design. With it, we target an important brain
protein with a broad range of implications for treating CNS disorders.
SUND-KU researchers and Ceremedy founders Birgitte Kornum (IN), Petrine Wellendorph (ILF) and Bente Frølund (ILF) have received a 3.5M DKK (c. 520,000 USD) pre-seed grant from the Novo Nordisk Foundation to continue and extend their efforts in CNS drug discovery. It is the second pre-seed grant for this purpose. The research will be carried out partly at SUND and partly through contract-based research....
In August 2018, the Novo Nordisk Foundation awarded a pre-seed grant of 3.5 mio DKK to support the research behind Ceremedy ApS. The grant is awarded to the University of Copenhagen and shared between Birgitte Kornum, Petrine Wellendorph and Bente Frølund....
Entrepeneur-in-Residence BiOrigin, with 15 years of expertise from pharma, venture investments, and management of biotech companies. Previously CEO of Pcovery ApS and part of the Novo Ventures investment.
Associate Professor at the University of Copenhagen, with more than 15 years of expertise in molecular pharmacology.
VP Medicinal Chemistry
Professor at the University of Copenhagen, with more than 20 years of expertise in small-molecule medicinal chemistry.
VP Translational Pharmacology
Associate Professor at the University of Copenhagen, with 15 years of expertise in human biology and in vivo neuroscience.